

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
	APPLICANT(S) Ross et al.	
	FILING DATE Herewith	GROUP 1646

JP973 U.S. PTO
09/96/1086
09/21/01 of 1

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Amplification of 4q21-q22 and the MXR Gene in Independently Derived Mitoxantrone-Resistant Cell lines, Thorid Knusten, V. Koneti Rao, Thomas Ried, Lyn Mickley, Erasmus Schneider, Keisuke Miyake, B. Michael Ghadimi, Hesed Padilla-Nash, Svetlana Pack, Lee Greeneberger, Kenneth Cowan, Michael Dean, Tito Fojo, and Susan Bates, Genes, Chromosomes and Cancer, Vol. 27 pp. 110-116.
AS	1	
AT	1	
EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

*Duplicate signed
submitted*

9/3/04

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 8-83) PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO.:

10460-7 (53836-5001)

APPLICATION NO.:

Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

(Form PTO-1449 Modified 5/95)
(Use several sheets if necessary)

APPLICANT:

D. Ross et al.

FILING DATE:

Herewith

GROUP ART UNIT:

1642

U.S. PATENT DOCUMENTS

EX. INT	DOCU- MENT	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EX. INT	DOCU- MENT	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
		WO 98/55614	December 1998	International			

Therapeutic Agent
9/3/04

OTHER DOCUMENTS (Including Author, Title, Date, Document No., etc.)

EXAMINER:

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 14 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 10460-7 (53836-5001)		APPLICATION NO. Not Yet Assigned
	APPLICANT(S) Ross et al.		
	FILING DATE Herewith		GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes
	AM1						No
	AN1						Yes
	AO1						No
	AP1						Yes
							No

Duplicate 9/2/04

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Atypical Multidrug Resistance: Breast Cancer Resistance Protein Messenger RNA Expression in Mitoxantrone-Selected Cell Lines. Douglas D. Ross, Weidong Yang, Lynne V. Abruzzo, William S. Dalton, Erasmus Schneider, Hermann Lage, Munfred Dietel, Lee Greenberger, Susan P.C. Cole, L. Austin Doyle. JNCI, Vol. 91, No. 5, 1/28/99, pp. 1-11.
AS	1	Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the Expressed Sequence Tags database. Rando Allikmets, Bernard Gerrard, Amy Hutchinson and Michael Dean, Human Molecular Genetics, 1996, Vol. 5, No.1, pp. 1649-1655.
AT	1	Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line. S.P.C. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M.V. Duncan, R.G. Deeley, Vol. 258, December 4, 1992, pp. 1650-1654.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.		APPLICATION NO.	
	10460-7 (53836-5001)		Not Yet Assigned	
	APPLICANT(S)			
	Ross et al.			
FILING DATE			GROUP	
Herewith			1646	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC1						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AD	1	Reduced Intracellular Drug Accumulation in the Absence of P-Glycoprotein (mdr1) Overexpression in Mitoxantrone-resistant Human MCF-7 Breast Cancer Cells, Masayuki Nakagawa, Erasmus Schneider, Katharine H. Dixon, Julie Horton, Kristin Kelly, Charles Morrow, Kenneth H. Cowan, Cancer Research, Vol. 52, 6175-6181, November 15, 1992.
	AE	1	Cross-Resistance to Camptothecin Analogues in a Mitoxantrone-resistant Human Breast Carcinoma Cell Line Is Not Due to DNA Topoisomerase I Alterations, Chih-Hsin J. Yang, Julie K. Horton, Kenneth H. Cowan and Erasmus Schneider, Cancer Research Vol. 55, pp. 4004-4009, September 15, 1995.
	AF	1	Characterization of Adriamycin-resistant Human Breast Cancer Cells Which Display Overexpression of a Novel Resistance-related Membrane Protein, Yi-Nan Chen, Lyn A. Mickley, Arnold M. Schwartz, Edward M. Action, Jaulang Hwang, and Antonio T. Fojo, The Journal of Biological Chemistry, Vol 265, No 17, pp10073-10080, June 15, 1999.
	AG	1	Membrane Vesicle Formation Due Acquired Mitoxantrone Resistance in Human Gastric Carcinoma Cell Line EP685-257, Manfred Dietel, Hartmut Arps, Hermann Lage and Axel Niendorf, Cancer Research, Vol. 50, 6100-6106, September 15, 1990.
	AH	1	Different Mechanisms of Decreased Drug Accumulation in Doxorubicin and mitoxantrone resistant variants of the MCF7 Human Breast Cancer Cell line, C.W. Taylor, W.S. Dalton, P.R. Parriar, M.C. Gleason, W.T. Bellamy, F.H. Thompson, D.J. Roe and J.M. Trent, J. Cancer Vol. 68, pp. 923-929, (1991).
	AI	1	Fumitremogilin C Reverse Multidrug Resistance in Cells Transfected with the Breast Cancer Resistance Protein, Sridhar K. Radindran, Douglas D. Ross, L. Austin Doyle, Weidong Yang, and Lee M. Greenberger, Cancer Research, Vol. 60, pp. 47-50, January 1, 2000.
	AJ	1	Analysis of MRP mRNA in Mitoxantrone-Selected, Multidrug-Resistant Human Tumor Cells, Bernard W. Futscher, Mohammad R. Abbaszadegan, Federick Domann, and William S. Dalton, Biochemical Pharmacology, Vol. 47, No. 9 pp. 1601-1606, 1994.
	AK	1	Cytogenetic and Phenotypic Analysis of a Human Colon Carcinoma Cell Line Resistant To Mitoxantrone, William S. Dalton, Anne E. Cress, David S. Alberts and Jeffery M. Trent, Cancer Research, Vol. 48, 1882-1888, April 1, 1988.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449		ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S) Ross et al.	
		FILING DATE Herewith	GROUP 1646

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AD	1	Reduced Drug Accumulation and Multidrug Resistance in Human Breast Cancer Cells without Associated P-Glycoprotein or MPR Overexpression, Jong Seok Lee, Stefania Scala, Yoshihito Matsumoto, Bruce Dickstein, Rob Robey, Zhirong Zhan, Guillermo Altenberg, and Susan E. Bates, Journal of Cellular Biochemistry Vol. 65, pp. 513-526, 1997.
	AE	1	Decreased Drug Accumulation in a Mitoxantrone-Resistant Gastric Carcinoma Cell Line in the Absence of P-Glycoprotein, Udo Kellner, Lesley Hutchinson, Andre Seidel, Hermann Lage, Mary K. Danks, Manfred Dietel and Scott H. Kaufmann, Int. J. Cancer Vol. 71, pp. 817-824, 1997.
	AF	1	Reduced Cellular Accumulation of Topotecan: a novel Mechanism of Resistance in a Human Ovarian Cancer Cell Line, J. Ma, M. Maliepaard, K. Nooter, WJ. Loos, H.J. Kolker, J. Verweij, G. Stoter and JHM Schellens, British Journal of Cancer, Vol. 77(10), pp. 1645-1652, 1998.
	AG	1	Reversal of a Novel Multidrug Resistance Mechanism in Human Colon Carcinoma Cells By Fumitremorgin C, Sridhar K. Rabindran, Haiyin He, Maya Singh, Eileen Brown, Karen I. Collins, Tami Annable, and Lee M. Greenberger, Cancer Research Vol. 58, pp. 5850-5858, December 15, 1998.
	AH	1	Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line, Marc Maliepaards, Margot A. Van Gastelen, Laurina A. de Jong, Dick Pluim, Robert C. A. M. van Waardenburg, Marjan C. Ruevekamp-Helmers, Ben G. J. Floot, and Jan H. M. Schellens, Cancer Research Vol. 59, pp. 4559-4563, September 15, 1999.
	AI	1	Expression of the Novel Mitoxantrone Resistance Associated Gene MXR7 in Colorectal Malignancies, H. Lage, M. Dietel, G. Froeschle, and Reymann, International Journal of Clinical Pharmacology and Therapeutics, Vol. 36, No. 1, page 58-60, 1998.
	AJ	1	The Mouse Bcrp1/Mxr/Abcp Gene: Amplification and Overexpression in Cell Lines Selected Resistance Topotecan, Mitoxantrone, or Doxorubicin, John D. Allen, Remco F. Brinkhuis, Jan Wijnholds and Alfred H. Schinkel, Cancer Research, 4237-424, September 1, 1999.
	AK	1	Multiple Mechanisms Confer Drug Resistance to Mitoxantrone in the Human 8226 Myeloma Cell Line, Lori A. Hazlehurst, Nils F. Foley, Mary C. Gleason-Guzman, Miles P. Hacker, Anne E. Cress, Lee W. Greenberger, Mariska C. De Jong, and William S. Dalton, Cancer Research, Vol. 59, pp. 1-8, March 1, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449	ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT		
APPLICANT(S) Ross et al.		
FILING DATE Herewith	GROUP 1646	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1					
	AB1					

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AD	1	Multidrug Resistance-associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etoposide Resistance, Erasmus Schneider, Julie K. Horton, Chih-Hsin Yang, Masayuki Nakagawa, and Kenneth H. Cowan, Cancer Research, Vol. 54, pp. 152-158, January 1, 1994.
AE	1	Isolated of Amplified and Overexpressed DNA sequences from Adriamycin-resistant Human Breast Cancer Cells, Craig R. Fairchild, S. Percy Ivy, Chien-Song Kao-Shan, Jacqueline Whang-Peng, Neal Rosen, Mark A. Israel, Peter W. Melera, Kenneth H. Cowan, and Merrill E. Goldsmith, Cancer Research, Vol 47, pp. 5141-5148, October 1, 1987.
AF		Reversion of Multidrug Resistance in the P-glycoprotein-positive Human Pancreatic Cell Line 1 (EPP85-181RDB) by Introduction of a Hammerhead Ribzyme, P.S. Holm, K.J. Scanlon, and M. Dietel.
AG	1	Novel Mechanisms of Drug Resistance in Leukemia, DD Ross, 2000
AH	1	Cloning of DNA Sequences from the White Locus of D. Melanogaster by a Novel and General Method, Cell, Vol. 25, pp. 693-704, September 1981.
AI	1	Studies on the Mechanism of Fatty Acid Synthesis, E.L. Pugh and Salih J. Wakil, The Journal of Biological Chemistry, Vol. 240, No. 12, December 1965.
AJ	1	DNA Sequence of the White Locus of Drosophila Melanogaster, Devin O'Hare, Christine Murphy, Robert Levis and Gerald M. Rubin, J. Mol. Biol. Vol. 180, pp. 437-455.
AK	1	Camptothecin Resistance: Role of the ATP-binding Cassette (ABC), Mitoxantrone-resistance Half Transporter (MXR), and Potential for Glucuronidation in MXR-expressing Cells, Cancer Research, Vol. 59, pp. 5938-5946, December 1, 1999
AL	1	Cellular Resistance to Actinomycin D in Chinese Hamster Cells in Vitro: Cross Resistance, Radioautographic and Cytogenetic Studies, June L. Biedler and Hansjorg Riehm, Cancer Research, Vol. 30, pp. 1174-1184, April 1970.
AM	1	Isolation of Amplified and Overexpressed DNA Sequences from Adriamycin-Resistant Human Breast Cancer Cells, Craig R. Fairchild, S. Percy Ivy, Chien-Song Kao-Shan, Jacqueline Whang-Peng, Neal Rosen, Mark A. Israel, Peter W. Melera, Kenneth H. Cowan, and Merrill E. Goldsmith, Cancer Research 47, pp. 5141-5148, October 1, 1987.
AN	1	Multidrug Resistance in Mitoxantrone-selected HL-60 Leukemia Cells in the Absence of P-Glycoprotein Overexpression, W. Grzydon Harker, D. Lynn Slade, William S. Dalton, Paul S. Meltzer and Jeffrey M. Trent, Cancer Research, Vol. 49, pp. 4542-4549, August 15, 1989.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 10460-7 (53836-5001)		APPLICATION NO. Not Yet Assigned	
	APPLICANT(S) Ross et al.			
	FILING DATE Herewith		GROUP 1646	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AC						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AD	1	New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, Philip Skehan, Ritsa Storeng, Dominic Scudiero, Anne Monks, James McMahon, David Vistica, Jonathan T. Warren, Heidi Bokesch, Susan Kenney, Michael R. Boyd, J National Cancer Institute, Vol. 82, No. 13, July 14, 1990
	AE	1	Derivation of Specific Antibody-Producing Tissue Culture and Tumor Lines By Cell Fusion, G. Kohler, and C. Milstein, Eur. J. Immunol., Vol 6, pp. 511-519, 1976.
	AF		Differential Display and Cloning of Messenger RNAs from Human Breast Cancer versus Mammary Epithelial Cells, Peng Liang, Lidia Averboukh, Khandan Keyomarsi, Ruth Sager, and Auther B. Pardee, Cancer Research, Vol. 52, pp. 6966-6968, December 15, 1992.
	AG	1	Reduced Permeability in CHO Cells as a Mechanism of Resistance to Colchicine, Victor Ling and Larry H. Thompson, J. Cell Physiol, Vol. 83, page 103-116.
	AH	1	Fusion between Immunoglobuline-secreting and Nonsecreting Myeloma Cell Lines, G. Kohler, and S.C. Howe and C. Milstein, Eur. J. Immunol., Vol. 6, pp. 292-295, 1976.
	AI	1	Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction, Peng Liang, and Arthur B. Pardee, Science, Vol. 257, pp. 967-971, August 14, 1992.
	AJ	1	Sequence of a cDNA from the Drosophila Melanogaster White Gene, Nucleic Acids Research, Vol. 18, No. 6, pp. 1633, February 20, 1990.
	AK	1	Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, G. Kohler, C. Milstein, Vol. 256, August 7, 1975.
	AL	1	Decreased Sensitivity of Carcinoembryonic Antigen cDNA-Transfected Cells to Adriamycin, Hitoshi Kawaharata, Yuji Hinoda, Fumio Itoh, Takao Endo, Shinzo Oikawa, Hiroshi Nakazato, and Kohzoh Imai, Int. J. Cancer, Vol. 72, pp. 377-382, 1997.
	AM	1	Two COOH-Terminal Truncated Cytoplasmic Forms of Topoisomerase II in a VP-16-Selected Lung Cancer Cell Line Results from Partial Gene Deletion and Alternative Splicing, Qiang Yu, Shelagh E. L. Mirski, Kathryn E. Sparks, and Susan P. C. Cole, Biochemistry, Vol. 36, pp. 5868-5877, 1997.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO 1 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO.	APPLICATION NO.
	10460-7 (53836-5001)	Not Yet Assigned
	APPLICANT(S)	
	Ross et al.	
	FILING DATE	GROUP
	Herewith	1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes
							No
	AM1						Yes
							No
	AN1						Yes
							No
	AO1						Yes
							No
	AP1						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	1	H19 Gene Overexpression in Atypical Multidrug-resistant Cells Associated with Expression of a 98-Kilodalton Membrane Glycoprotein, L. Austin, Weidong Yang, Arung, Arun K. Rishi, Yongming Gao, and Douglas D. Ross, Cancer Research 56, 2904-2904, July 1, 1996.
	AS	1	A multidrug resistance transporter from human MCF-7 breast cancer cells, L. Austin Doyle, Weidong Yang, Lynne V. Abruzzo, Tammy Krogmann, Yongming Gao, Arun K. Rishi, and Douglas D. Ross. Proc. Natl. Acad. Sci. USA, Vol 95, pp. 15665-15670, December 1998, Medical Sciences.
	AT	1	A Human Placenta-Specific ATP-Binding Cassette Gene (ABCP) on Chromosome 4q22 That Is Involved in Multidrug Resistance. Rando Allikmets, Lynn M. Schriml, Amy Hutchinson, Vincenzo Ramano-Spica, and Michael Dean, Cancer 5337-5339, December 1, 1998.
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO 14 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 10460-7 (53836-5001)	APPLICATION NO. Not Yet Assigned
	APPLICANT(S) Ross et al.	
	FILING DATE Herewith	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes
	AM1						No
	AN1						Yes
	AO1						No
	AP1						Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Molecular Cloning of cDNAs Which Are Highly Overexpressed in Mitoxantrone resistant Cells: Demonstration of Homology to ABC Transport Genes. Keisuke Miyake, Lyn Mickle, Tomas Litman, Zhirong Zhan, Robert Robey, Barbara Cristensen, Marifiorella Brangi, Lee Green Berger, Michael Dean, Tito Fojo, and Susan E. Bates, Cancer Research 59, 8-13, January 1, 1999.
AS	1	A Human Canalicular Multispecific Organic Anion Transporter (cMOAT) Gene Is Overexpressed in Cisplatin-resistant Human Cancer Cell Lines with Decreased Drug Accumulation. Ken Taniguchi, Morimase Wada, Kimitoshi Kohno, Takanori Nakamura, Takeshi Kawabe, Mina Kawakami, Kazuhiro Kagotani, Katsuzumi Okumura, Shin-ichi Akiyama, and Michihiko Kuano, Cancer Research 56 4124-4129, September 15, 1996.
AT	1	Cloning of the cDNA for a Human Homologous 21q22.3 gene of the Drosophila White Gene and Mapping to Chromosome 21q22.3: Haiming Chen, Colette Rossier, Maria D. Lalioti, Audrey, Lynn, Aravinda Chakravarti, Caelle Perrin, and Stylianos E. Antonarakis, Am. J. Genet. 59:66-75, 1996.
EXAMINER		DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.		